American pharmaceutical company
Gilead Sciences ▸ Facts ▸ Comments ▸ News ▸ Videos
Gilead's remdesivir gets conditional EU clearance
Credit: Reuters Studio Duration: 00:59Published
Gilead to Charge $3,120 Per Patient for Typical Covid-19 Treatment
Credit: Wochit News Duration: 00:35Published
AstraZeneca shares down after report it approached Gilead
Credit: Reuters Studio Duration: 01:09Published
Stocks rise on recovery hopes
Credit: Reuters Studio Duration: 01:22Published
EU close to fast-tracking COVID-19 treatment drug
Credit: Reuters Studio Duration: 01:40Published
WHO sees 'potentially positive data' in treating coronavirus
Credit: Reuters Studio Duration: 01:12Published
You Might Like
Trump ‘Undermining’ Global Fight Against Covid By Hoarding New Drug, Minister WarnsDonald Trump risks “undermining” global collaboration on Covid-19 by buying up the world’s supplies of a drug treatment for the virus, the British government has warned. Business minister Nadhim..
Coronavirus: US buys nearly all of Gilead's Covid-19 drug remdesivirThe US will acquire almost all the next three months' production of the drug from Gilead.
Virus-fighting drug's cost announcedGilead Sciences said it will charge the U.S. government and other developed countries $390 per vial for its coronavirus-fighting drug remdesivir, or about $2,340 for a typical five-day course of..
Remdesivir, the First Coronavirus Drug, Gets a Price TagFederal health officials and Gilead Sciences have settled on priority distribution to Americans — and nonnegotiable pricing.
Coronavirus updates: More states close bars, slow reopening plans; Gilead Sciences sets price for remdesivir treatmentsCalifornia Gov. Gavin Newsom ordered some bars to close. Arizona and Washington slow down reopenings. Latest coronavirus news.
FDA warns against co-administration of remdesivir with CQ or HCQ for COVID-19 patientsHyderabad, June 16 () The US Food and Drug Administration (USFDA) warned healthcare providers against co-administration of Gilead Sciences remdesivir, which received emergency use authorization for..
FDA warns against combination of malaria drug and Gilead's remdesivirThe U.S. Food and Drug Administration on Monday issued a warning to healthcare providers against administering malaria drug hydroxychloroquine or chloroquine in combination with Gilead Sciences'..
Also reported by •Reuters
India's Zydus Cadila to make Gilead's potential COVID-19 drug remdesivirIndian drugmaker Zydus Cadila said on Friday it signed a non-exclusive licensing pact with Gilead Sciences Inc to manufacture and market antiviral drug remdesivir, the first treatment to show..
India's Zydus Cadila signs pact with Gilead to make remdesivirIndian drugmaker Zydus Cadila said on Friday it signed a non-exclusive agreement with Gilead Sciences Inc to manufacture and market antiviral drug remdesivir, the first treatment to show improvement in..
Singapore approves remdesivir drug for emergency COVID-19 treatmentSingapore on Wednesday approved the use of Gilead Sciences Inc's antiviral drug remdesivir for the treatment of severely ill patients with COVID-19 infection.
Gilead's remdesivir prevents lung damage in COVID-19 study on monkeysGilead Sciences Inc's antiviral drug remdesivir prevented lung disease in macaque monkeys infected with the new coronavirus, according to a study published in the journal Nature on Tuesday.
AstraZeneca contacted Gilead over potential megamerger: Bloomberg NewsBritain's AstraZeneca has approached U.S. rival Gilead Sciences about a possible merger to form one the world's largest drug companies, Bloomberg News reported on Sunday, citing people familiar with..
Gilead's remdesivir could see $7 billion in annual sales on stockpiling boost: analystGilead Sciences Inc's potential COVID-19 treatment, remdesivir, could bring in more than $7 billion in annual sales by 2022, spurred by governments stockpiling the drug to guard against future..
India approves Gilead's remdesivir to treat severe COVID-19 casesIndia's government has approved Gilead Sciences Inc's antiviral drug remdesivir for emergency use for five doses in treating COVID-19 patients.
Also reported by •WorldNews
Gilead's next step on coronavirus: inhaled remdesivir, other easier-to-use versionsGilead Sciences Inc is developing easier-to-administer versions of its antiviral treatment remdesivir for COVID-19 that could be used outside of hospitals, including ones that can be inhaled, after..
Also reported by •Reuters India
India's drug regulator grants Gilead Sciences marketing authorisation for remdesivirIndia's drug regulator has granted US pharma giant Gilead Sciences marketing authorisation for its anti-viral drug remdesivir for "restricted emergency use" on hospitalised Covid-19 patients in view of..
Gilead's remdesivir shows modest improvement in moderate COVID-19 patientsGilead Sciences Inc on Monday reported that its antiviral drug remdesivir provided a modest benefit in patients with moderate COVID-19 given a five-day course of the treatment, while those who received..
Gilead says drug helped moderately ill coronavirus patientsA California biotech company says its experimental drug remdesivir improved symptoms when given for five days to moderately ill, hospitalized patients with COVID-19. Gilead Sciences gave few details on..
European, South Korean authorities vie for COVID-19 antiviral remdesivirEuropean and South Korean authorities are vying for Gilead Sciences' potential COVID-19 treatment, remdesivir, even though the drugmaker has yet to gain regulatory approval in either market and is..
South Korea seeks to import anti-viral remdesivir as new coronavirus cases emergeSouth Korean health authorities said on Friday they would request imports of Gilead Sciences Inc's anti-viral drug remdesivir to treat COVID-19, as new outbreaks of the disease flare as social..
Gilead study shows shorter five-day course of remdesivir works as well as 10-day oneGilead Sciences Inc, which has suggested that a shorter treatment duration could extend limited supplies of its drug remdesivir, on Wednesday published results of a study showing no significant..
Britain to provide anti-viral drug remdesivir to some COVID-19 patientsBritain will provide the anti-viral drug remdesivir to certain COVID-19 patients that it is most likely to benefit as part of a collaboration with manufacturer Gilead Sciences, the health ministry said..
NIH trial: Gilead's drug works best in COVID patients on oxygenThe U.S. National Institutes of Health (NIH) on Friday said that data from its trial of Gilead Sciences Inc's remdesivir show that the drug offers the most benefit for COVID-19 patients who need extra..
Peer-reviewed data shows Gilead's drug helps COVID-19 recovery timeThe U.S. National Institutes of Health (NIH) said on Friday peer-reviewed data published in the New England Journal of Medicine show that Gilead Sciences Inc's remdesivir is effective at helping..
U.S. doctors call for remdesivir data to guide coronavirus treatmentU.S. doctors and others in the scientific community are calling for the release of data that convinced health regulators to authorize emergency use of Gilead Sciences Inc's antiviral drug remdesivir to..
Also reported by •Reuters
Remdesivir close to EU's initial authorisation as COVID-19 treatmentThe head of the European Union's medicines agency Guido Rasi said on Monday an initial authorisation for U.S. pharmaceutical company Gilead's remdesivir as a COVID-19 treatment could be granted in..
Part of Gilead's coronavirus drug donation allocated to JapanJapan has begun treating severely ill COVID-19 patients with Gilead Sciences Inc's coronavirus drug remdesivir, days after granting emergency approval to the medication the company is supplying as part..
Health groups ask India to rescind Gilead's patents for COVID-19 drug remdesivirTwo health advocacy groups have written to the Indian government asking it to rescind patents given to Gilead Sciences for the drug remdesivir so it can be distributed more fairly to coronavirus..
Japan says drugmaker Gilead's COVID-19 treatment remdesivir now in use in hospitalsJapan has begun treating severely ill COVID-19 patients with Gilead Sciences Inc's COVID-19 remdesivir drug, a health ministry official said, just days after giving the drug emergency approval as it..
Gilead signs pact with generic drugmakers in India to expand supply of experimental COVID-19 drug remdesivirGlobally, the virus has infected a total of 4.23 million people as of now while the number of deaths has reached 290000.
Gilead ties up with generic drugmakers for COVID-19 drug supplyGilead Sciences Inc said on Tuesday it has signed non-exclusive licensing pacts with five generic drugmakers based in India and Pakistan to expand the supply of its experimental COVID-19 treatment..
India's Jubilant signs licensing deal for Gilead's COVID-19 drugIndia's Jubilant Life Sciences Ltd said on Tuesday it had signed a non-exclusive licensing agreement for selling Gilead Sciences Inc's experimental COVID-19 treatment remdesivir in 127 countries,..
U.S. to allow states to distribute Gilead's remdesivir to fight COVID-19The U.S. Department of Health and Human Services (HHS) said on Saturday it would allow state health departments to distribute Gilead Sciences Inc's remdesivir drug to fight COVID-19, and the United..
Exclusive: Iran-linked hackers recently targeted coronavirus drugmaker Gilead - sourcesHackers linked to Iran have targeted staff at U.S. drugmaker Gilead Sciences Inc in recent weeks, according to publicly-available web archives reviewed by Reuters and three cybersecurity researchers,..
Japan approves Gilead Sciences' remdesivir as COVID-19 drugJapan has approved Gilead Sciences Inc's remdesivir as a treatment for COVID-19, the health ministry said on Thursday, making it the country's first officially authorised drug for the disease.
Will Gilead price its coronavirus drug for public good or company profit?Gilead Sciences Inc faces a new dilemma in deciding how much it should profit from the only treatment so far proven to help patients infected with the novel coronavirus.
Also reported by •Reuters India
Gilead in talks to expand global supply of COVID-19 drug remdesivirGilead Sciences Inc said on Tuesday it was in discussions with chemical and drug manufacturers to produce its experimental COVID-19 drug remdesivir for Europe, Asia and the developing world through at..
Coronavirus treatment drug remdesivir to arrive in hospitals this week, Gilead CEO saysThe CEO of Gilead Sciences says U.S. hospitals should get enough of its drug to fight COVID-19 to treat as many as 200,000 patients this week.
Japan aims to fast-track review of anti-viral drug remdesivirJapan will fast-track a review of Gilead Sciences Inc's antiviral drug remdesivir so that it can hopefully be approved for domestic COVID-19 patients a week after the U.S. firm's filing for such..
U.S. emergency approval broadens use of Gilead's COVID-19 drug remdesivirGilead Science Inc's antiviral drug remdesivir was granted emergency use authorization by the U.S. Food and Drug Administration for COVID-19 on Friday, clearing the way for broader use of the drug in..